HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Glenmark to introduce higher strength of FabiFlu
Aug-06-2020
Glenmark Pharmaceuticals is going to introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

  RELATED NEWS >>